1. Home
  2. YDDL vs EDIT Comparison

YDDL vs EDIT Comparison

Compare YDDL & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YDDL

One and One Green Technologies. Inc Class A Ordinary Shares

N/A

Current Price

$5.05

Market Cap

275.4M

ML Signal

N/A

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.46

Market Cap

233.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YDDL
EDIT
Founded
2014
2013
Country
Philippines
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.4M
233.3M
IPO Year
2025
2016

Fundamental Metrics

Financial Performance
Metric
YDDL
EDIT
Price
$5.05
$2.46
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$4.13
AVG Volume (30 Days)
81.6K
1.6M
Earning Date
11-17-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
310.92
N/A
EPS
0.15
N/A
Revenue
$62,922,700.00
$46,383,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$32.89
N/A
Revenue Growth
118.15
N/A
52 Week Low
$3.61
$0.91
52 Week High
$8.89
$4.54

Technical Indicators

Market Signals
Indicator
YDDL
EDIT
Relative Strength Index (RSI) N/A 44.41
Support Level N/A $2.09
Resistance Level N/A $2.70
Average True Range (ATR) 0.00 0.17
MACD 0.00 0.05
Stochastic Oscillator 0.00 59.84

Price Performance

Historical Comparison
YDDL
EDIT

About YDDL One and One Green Technologies. Inc Class A Ordinary Shares

One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of Philippines. The company process raw materials and generate final products that include copper alloy ingot, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap and industrial recycling. By providing lower-cost alternatives for processing recycled materials, It is not only Contributing to environmental sustainability but also highlight its role as a modern and specialized recycling company.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: